Breakthrough for allergy vaccination  

Danish biopharmaceutical company ALK-Abelló has presented good results from a major allergy study

Allergy vaccination with Alutard SQ, produced by the Danish biopharmaceutical company ALK-Abelló, has been documented to be an effective treatment of hay fever caused by grass pollen. Results from the world’s largest clinical study of allergy vaccination have been presented at a US congress for specialist physicians in allergy. Leading researchers are reportedly referring to the results as an international breakthrough.


In the UK where the clinical study was carried out, 10% of the population suffers from grass allergy. In Denmark and the rest of Europe the proportion is estimated to be around 7%. MD of ALK-Abelló Jens Bager comments that although Alutard SQ has been on the market for some years, the new test results confirm that allergy vaccination should have a central role in the treatment of allergy in the future. ALK-Abelló is a world leader in allergy vaccination and a part of the Chr. Hansen Group. The news is reported by national broadsheet Jyllands-Posten.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×